iSpecimen Inc. Completes $5M Public Offering

What Happened

• iSpecimen Inc. (ISPC) announced it closed a “reasonable best efforts” public offering on August 7, 2026. The Company sold 996,231 shares of common stock and issued pre-funded warrants to purchase up to 2,849,923 additional shares for aggregate proceeds of $5,000,000 (or $5,000,285 if the pre-funded warrants are fully exercised). E.F. Hutton & Co. served as placement agent.

Key Details

• Offering closed: August 7, 2026; Registration: Form S-1 (File No. 333-297001) declared effective July 30, 2026.
• Securities sold: 996,231 common shares + pre-funded warrants to buy up to 2,849,923 shares.
• Gross proceeds: $5,000,000 (or $5,000,285 with full exercise); placement agent fee: 4.0% of gross proceeds plus certain expense reimbursements and a 1% non-accountable expense allowance.
• Use of proceeds: repayment of outstanding liabilities, potential acquisitions or investments, marketing/advertising, with remaining proceeds for working capital.

Why It Matters

• The financing provides near-term liquidity (about $5.0M) to fund operations, pay debts, and pursue potential acquisitions or investments without relying solely on operating cash flow.
• The issuance of pre-funded warrants could add share dilution if exercised; investors should watch for future exercises and any related impact on share count and per-share metrics.
• Placement agent fees and reimbursements reduce net proceeds; the filing also includes the related agreements and a press release disclosing pricing and closing.